Atopic Dermatitis

Organon reports pooled phase 3 data showing tapinarof cream (VTAMA) improved atopic dermatitis severity across pediatric and adult age groups by Week 8.

Walter Liszewski, MD, discusses how dermatologists can personalize atopic dermatitis treatment using biologics, JAK inhibitors, and topicals.

Sanofi has discontinued development of OX40L-targeting amlitelimab for atopic dermatitis, following the heels of Kyowa Kirin's similar rocatinlimab discontinuation.

Jason Hawkes, MD, explains how new biologics and targeted therapies are advancing precision medicine and improving personalized care in atopic dermatitis.

Experts unpack where new eczema creams fit, and why insurance hurdles and steroid fear keep patients from faster itch relief.

New secondary endpoint analyses from Phase 3 LATITUDE PsO 3001 and 3002 reveal high rates of clearance on high-impact areas.

These positive topline findings highlight the investigational TYK2 inhibitor soficitinib (ICP-332) in patients with moderate-to-severe atopic dermatitis.

Matthew Zirwas, MD, speaks in this SDPA interview about evidence for atopic dermatitis being more of an environmental disease than a genetic one.

New phase 2 findings on tralokinumab, from TRAPEDS-1, show favorable results in children 6 - 11 years with atopic dermatitis.

The supplemental New Drug Application for Arcutis’ roflumilast cream 0.05% (Zoryve) is for mild to moderate atopic dermatitis in those down to 3 months.

This review highlights the most notable dermatology news stories covered by HCPLive during the second quarter of 2026.

Matthew Zirwas, MD, on why adult-onset atopic dermatitis is the most undertreated condition in dermatology and how diagnostic criteria are driving years of delayed care.

The topic of precision medicine in dermatology is explored in this segment of Bunick's interview at RAD 2026.

This interview at RAD highlights FDA-approved therapies in the atopic dermatitis treatment armamentarium.

Matthew Zirwas, MD, explains why topical JAK inhibitors represent a clinical turning point for hand eczema.

Matthew Zirwas, MD, on using dupilumab and lebrikizumab to guide patch testing decisions and the 2 most missed allergens in eczematous disease.

Siegfried discusses some of the most notable highlights of her session at the RAD 2026 conference regarding clinical pearls in dermatology.

This segment of Lio's RAD Conference interview in Nashville highlights the growing number of therapeutics and an increasingly personalized approach.

Pediatric studies show dupilumab boosts height gains, eases caregiver-reported symptoms by week 2, and maintains strong skin clearance for 3 years.

This Q&A interview with Mona Shahriari, MD, highlights key atopic dermatitis tips, new developments, and themes from her session at RAD 2026.

Mona Shahriari, MD, spoke about the evolving understanding of atopic dermatitis as a systemic disease, the complexities of treatment selection, and more.

Multiple trials at RAD 2026 highlight the efficacy and safety of delgocitinib in chronic hand eczema.

RAD 2026 data indicate tralokinumab achieved significantly deeper hand eczema clearance and greater functional improvement than dupilumab in an indirect comparison.

Roflumilast cream data from RAD 2026 shed further light on the efficacy and safety across the age spectrum.

Nguyen urges clinicians to consider patient's disease presentation, comorbidities, treatment goals, and preferences when making therapeutic decisions.